BidaskClub upgraded shares of ZIOPHARM Oncology (NASDAQ:ZIOP) from a sell rating to a hold rating in a report released on Saturday morning.

Other equities analysts have also recently issued reports about the stock. HC Wainwright set a $6.00 price objective on shares of ZIOPHARM Oncology and gave the company a buy rating in a research note on Tuesday, November 13th. Raymond James raised shares of ZIOPHARM Oncology from a market perform rating to an outperform rating and set a $5.00 price objective on the stock in a research note on Thursday, November 15th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. The company currently has an average rating of Hold and an average price target of $5.33.

Shares of ZIOP stock opened at $3.07 on Friday. ZIOPHARM Oncology has a 52-week low of $1.90 and a 52-week high of $5.24. The company has a market capitalization of $455.61 million, a price-to-earnings ratio of -5.79 and a beta of 1.85.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. MetLife Investment Advisors LLC raised its holdings in ZIOPHARM Oncology by 77.1% in the second quarter. MetLife Investment Advisors LLC now owns 65,990 shares of the biotechnology company’s stock worth $199,000 after purchasing an additional 28,734 shares during the period. Teachers Advisors LLC raised its holdings in ZIOPHARM Oncology by 11.3% in the third quarter. Teachers Advisors LLC now owns 318,834 shares of the biotechnology company’s stock worth $1,020,000 after purchasing an additional 32,294 shares during the period. Raymond James & Associates raised its holdings in ZIOPHARM Oncology by 168.3% in the second quarter. Raymond James & Associates now owns 58,290 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 36,568 shares during the period. Northern Trust Corp raised its holdings in ZIOPHARM Oncology by 2.7% in the second quarter. Northern Trust Corp now owns 1,623,297 shares of the biotechnology company’s stock worth $4,902,000 after purchasing an additional 42,905 shares during the period. Finally, Alliancebernstein L.P. raised its holdings in ZIOPHARM Oncology by 18.6% in the third quarter. Alliancebernstein L.P. now owns 277,830 shares of the biotechnology company’s stock worth $889,000 after purchasing an additional 43,611 shares during the period. Institutional investors own 39.95% of the company’s stock.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.

Recommended Story: Capital Gains

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.